Recipharm has entered into a long-term agreement with Sato Pharmaceutical Co. for the commercial manufacture and delivery of the Emla Patch to Japan. Emla Patch is used as a local anaesthetic product and will be launched under the business area of ethical pharmaceuticals at Sato. Recipharm’s facility in Karlskoga, Sweden will produce and deliver the product to Sato, which has headquarters in Tokyo. Recipharm says after a successful launch in Japan, it is expected that the annual volumes of Em...